Last reviewed · How we verify
NCT06245759
The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients
trial testing This was a retrospective study and no patient intervention was performed in Non-Muscle-Invasive Bladder Cancer in 120,000 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Huazhong University of Science and Technology |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 120,000 |
| Start date | 31 August 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- This was a retrospective study and no patient intervention was performed
Conditions studied
- Non-Muscle-Invasive Bladder Cancer — all drugs for Non-Muscle-Invasive Bladder Cancer →
- Bladder Cancer — all drugs for Bladder Cancer →
Sponsor
Huazhong University of Science and Technology
Who can join
18 and older, any sex, with Non-Muscle-Invasive Bladder Cancer or Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Based on large sample size studies at home and abroad, the prognosis of patients with non-muscular invasive bladder cancer in different sites undergoing transurethral bladder tumor resection was determined, providing important guidance for subsequent clinical treatment and surgical instrument development.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The prognostic impact of tumor location in nonmuscle-invasive bladder cancer patients undergoing transurethral resection: insights from a cohort study utilizing Chinese multicenter and SEER registries.
Liu L, Li K, Wang SG, Wang J, et al · · 2024 · cited 6× · PMID 38788195 · DOI 10.1097/js9.0000000000001675
Verify or expand the search:
- PubMed search for NCT06245759
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Muscle-Invasive Bladder Cancer
Currently open trials in the same condition.
- NCT06972771 — Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer · recruiting
Other Huazhong University of Science and Technology trials
Trials by the same sponsor.
- NCT07502027 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Tr · Phase 4 · not yet recruiting
- NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
- NCT07509866 — Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone or Dexmedetomidine as Adjuncts for Adductor Canal · NA · recruiting
- NCT07326943 — Minimum Effective Dose of Ropivacaine for Ultrasound-guided Interscalene Block · NA · recruiting
- NCT07229976 — Clinical Efficacy of Thumbtack Needle for Chronic Insomnia in Perimenopausal and Menopausal Women · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06245759 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huazhong University of Science and Technology
- Last refreshed: 7 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06245759.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing